International Journal of Antimicrobial Agents
Volume 36, Issue 3 , Pages 230-233 , September 2010

Antimicrobial activity of DW286 against Streptococcus pneumoniae

  • Hee Soo Park

      Affiliations

    • School of Life Sciences, Handong Global University, Puk-ku, Pohang City, Kyungbuk 791-708, South Korea
    • ,
  • Sung Ji Jung

      Affiliations

    • School of Life Sciences, Handong Global University, Puk-ku, Pohang City, Kyungbuk 791-708, South Korea
    • ,
  • Dong-Rack Choi

      Affiliations

    • Dong Wha Pharmaceutical Industry Ltd., Anyang City, South Korea
    • ,
  • Jin-Hwan Kwak

      Affiliations

    • School of Life Sciences, Handong Global University, Puk-ku, Pohang City, Kyungbuk 791-708, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 54 260 1353; fax: +82 54 260 1925.

Received 5 February 2010 ,Accepted 7 April 2010.

References 

  1. Bartlett JG, Grundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618–1624
  2. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. 2004;48:2101–2107
  3. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 2002;34:1613–1620
  4. Liñares J, de la Campa AG, Pallares R. Fluoroquinolone-resistance in Streptococcus pneumoniae. N Engl J Med. 1999;341:1546–1547[author reply 1547–8]
  5. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347–382
  6. MacGowan AP. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opin Investig Drugs. 1999;8:181–199
  7. Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis. 2003;37:1210–1215
  8. Yun HJ, Min YH, Lim JA, Kang JW, Kim SY, Kim MJ, et al. In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic. Antimicrob Agents Chemother. 2002;46:3071–3074
  9. Kim MJ, Yun HJ, Kang JW, Kim S, Kwak JH, Choi EC. In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates. J Antimicrob Chemother. 2003;51:1011–1016
  10. Yun HJ, Min YH, Jo YW, Shim MJ, Choi EC. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV. Int J Antimicrob Agents. 2005;25:334–337
  11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. Document M100-S15. Wayne, PA: CLSI; 2005.
  12. Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996;40:2321–2326
  13. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998;42:2032–2035
  14. Bliss CI. Statistics in bioassay. New York, NY: Academic Press, Inc.; 1985;
  15. Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother. 2002;49:709–712

PII: S0924-8579(10)00195-0

doi: 10.1016/j.ijantimicag.2010.04.007

International Journal of Antimicrobial Agents
Volume 36, Issue 3 , Pages 230-233 , September 2010

Article Tools